期刊文献+

低剂量硼替佐米联合地塞米松及阿霉素治疗多发性骨髓瘤疗效观察 被引量:6

下载PDF
导出
摘要 目的观察低剂量硼替佐米联合地塞米松及阿霉素治疗多发性骨髓瘤的临床疗效。方法选择曲靖市第二人民医院2012年1月至2015年1月收治的65例多发性骨髓瘤患者作为研究对象,根据治疗方案的不同分为观察组(33例)和对照组(32例)。观察组患者给予硼替佐米的剂量为1.0-1.1 mg/m2,再予以10 mg/m2的阿霉素及40 mg地塞米松;对照组患者给予硼替佐米剂量为1.2-1.3 mg/m2,其余治疗方案同观察组相同。比较两组患者的治疗有效率、疾病控制率、疾病进展时间、不良反应及术后生活质量改善情况。结果两组患者治疗有效率、疾病控制率、疾病进展时间及生活质量改善情况比较,差异无统计学意义(P〉0.05);但观察组恶心、呕吐和带状疱疹等不良反应发生情况优于对照组,差异有统计学意义(P〈0.05)。结论低剂量的硼替佐米联合地塞米松和阿霉素具有与常规剂量硼替佐米治疗方案同样的治疗效果,且不良反应相对更少。
出处 《现代医药卫生》 2016年第21期3364-3365,共2页 Journal of Modern Medicine & Health
  • 相关文献

参考文献10

二级参考文献85

  • 1Terpos E,Roussou M,Dimopoulos MA.Bortezomib in multiple myeloma[J].Expert Opin Drug Metab Toxicol,2008,4(5):639-654.
  • 2Blade J,SamsonD,Reece D,et al.Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and hemopoietic stem cell transplantation.Myeloma Subcommittee of the EMBT.European Group for Blood and Marrow Transplant[J].Br J Haematol 1998,102(5):1115-1123.
  • 3Durie BG,Harousseau JL,Miguel JS,et al.International uniform response criteria for multiple myeloma[J].Leukemia,2006,20(9):1467-1473.
  • 4Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events,Version3.0,DCID,NIC,DHHD[S/OL].[2003-03-31].http://ctep.cancer.gov.
  • 5Richardson PG,Barlogie B,Berenson J,et al.A phase 2 study of bortezomib in relapsed,refactory myeloma[J].N Engl J Med,2003,348(26):2609-2617.
  • 6Jakubowiak AJ,Griffith KA,Reece DE,et al.Lenalidomide,bortezomib,pegylated liposomal doxorubicin,and dexamethasone in newly diagnosed multiple myeloma:a phase 1/2 Multiple Myeloma Research Consortium trial[J].Blood,2011,118(3):535-543.
  • 7Oken MM,Harrihgton DP,Abranson N,et al.Comparision of melphalan and prednisone with vincyistine,carmustime melphlan,cyclophospham and prednisone in the treatment of multiple myeloma.Results of Eastern Cooperative Oncology Study E 2479[J].Cancer,1997,79(8):1561-1567.
  • 8Yang SH,Teng HW,Hong YC,et al.International Staging System predicts prognosis of Chinese patients with multiple myeloma across different calendar periods with application of novel agents[J].Ann Hematol,2011.[Epub ahead of print].
  • 9Rajkumar SV,Kyle RA.Multiple myeloma diagnosis and treatment[J].Mayo Clin Proc,2005,80(10):1371-1382.
  • 10Jagannath S,Richardson PG,Sonneveld P,et al.Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and3 trials[J].Leukemia,2006,21(1):151-157.

共引文献232

同被引文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部